Recent Finacing
Recent Raise
NightstaRx develops AAV-delivered, one-time gene therapies for inherited retinal diseases, advancing NSR-REP1 (choroideremia) and NSR-RPGR (X-linked retinitis pigmentosa) through clinical trials from Boston and London.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors